Business Context and Reporting Period
This Form 8-K Current Report, dated March 8, 2019, is filed by Arsanis, Inc. (the "Registrant") regarding a material definitive agreement and an amendment to a merger agreement. The filing supplements the Definitive Proxy Statement for a special stockholder meeting scheduled for March 11, 2019, to approve the merger of Arsanis with X4 Pharmaceuticals, Inc. ("X4"). The report details a settlement with the Austrian funding agency FFG and the resulting adjustments to the merger terms.
Key Financial Metrics and Agreements
- Settlement Liability: Arsanis GmbH agreed to repay outstanding loan principal of EUR 8,505,204 (approximately $9.5 million USD) to FFG.
- Payment Schedule: Repayment is accelerated to a three-year schedule (ending June 30, 2021) instead of five years. The 2019 payment obligation is EUR 2,596,320 (approximately $2.9 million USD), due March 31, 2019.
- Liquidity Covenant: Arsanis GmbH must maintain a minimum cash balance equal to 70% of the then-outstanding loan principal in an Austrian bank account until full repayment.
- Merger Adjustment: The merger agreement was amended to deduct one-third of the 2019 payment (EUR 865,440, approx. $968,600 USD) from Arsanis's "net cash" at closing.
- Pro Forma Ownership: Based on the amended terms, Arsanis stockholders are estimated to own approximately 31.5% of the combined company, while X4 stockholders will own approximately 68.5%.
Material Changes Versus Prior Period
The primary material change is the amendment to the Agreement and Plan of Merger dated November 26, 2018. Previously, the approximately EUR 8.5 million in FFG loans were excluded from the deduction for unpaid indebtedness when calculating Arsanis's "net cash" at closing. The amendment reduces this excluded amount by the "Arsanis accelerated payment amount" (EUR 865,440), effectively lowering the net cash calculation to approximately EUR 7.6 million. This adjustment increases the exchange ratios for X4 common and preferred stock to approximately 0.5632 shares of Arsanis common stock for each share of X4 capital stock.
Outlook, Risks, and Contingencies
- Operational Covenants: Arsanis GmbH must maintain a physical premises in Austria with a minimum of eight full-time equivalent employees until at least December 31, 2021, and retain ownership of IP generated from FFG-funded projects.
- Default Consequences: Breach of the Settlement Agreement obligations allows FFG to accelerate repayment of all outstanding loans.
- Merger Risks: Risks include the inability to complete the merger, failure to obtain stockholder or regulatory approvals, and uncertainties regarding clinical trial results for X4's product candidate X4P-001.
- Forward-Looking Statements: The filing contains forward-looking statements regarding the merger completion, exchange ratios, and future capital needs, which are subject to significant risks and uncertainties.
Investor Verification Checklist
- Verify the final exchange ratio of 0.5632 Arsanis shares per X4 share and the resulting 31.5% / 68.5% ownership split.
- Confirm the March 31, 2019, cash outflow of approximately $2.9 million USD required for the FFG settlement.
- Review the Definitive Proxy Statement for full details on the merger conditions and the FFG Settlement Agreement.
- Monitor the status of the special stockholder meeting scheduled for March 11, 2019, for approval of the merger.
- Assess the impact of the 70% minimum cash balance requirement on Arsanis GmbH's liquidity and operational flexibility.